David Brill, MD
Cardiovascular Disease · Rockville, MDNPI 1164483822
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $731 and has fallen 96.1% since, to $29 in 2025.
Across 78 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$371
- Novartis$297
- Johnson & Johnson$195
- Edwards Lifesciences$183
- Boston Scientific$165
- Medtronic$84
- plus $715 from 23 others
Across 17 payments — averaging $4800.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$77K
- Abbott$5K
What the payments were for
- Travel & lodging$1578%
- Food & beverage$1,85392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $371 |
| Novartis | 15 | $297 |
| Johnson & Johnson | 5 | $195 |
| Edwards Lifesciences | 8 | $183 |
| Boston Scientific | 3 | $165 |
| Medtronic | 2 | $84 |
| Amgen | 3 | $63 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Merck | 3 | $51 |
| Atricure, Inc. | 2 | $48 |
| Pfizer | 3 | $44 |
| Cardiovascular Systems Inc. | 2 | $39 |
| Penumbra, Inc. | 1 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Cook Medical LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| W. L. Gore & Associates, Inc. | 2 | $30 |
| Immunitybio, Inc. | 1 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Bayer | 1 | $22 |
| Vital Connect, Inc | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Shockwave Medical, Inc | 1 | $19 |
| Silk Road Medical, Inc. | 1 | $18 |
| Stryker | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,010 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $238,549 |
| EntrestoSacubitril/Valsartan | 118 | $142,743 |
| XareltoRivaroxaban | 41 | $63,954 |
| JardianceEmpagliflozin | 24 | $29,413 |
| Repatha SureclickEvolocumab | 21 | $24,048 |
| Praluent PenAlirocumab | 15 | $19,545 |
| BrilintaTicagrelor | 19 | $18,539 |
| Ranolazine ErRanolazine | 52 | $7,717 |
| VascepaIcosapent Ethyl | 13 | $6,576 |
| Rosuvastatin Calcium | 241 | $6,567 |
| Metoprolol Succinate | 318 | $6,175 |
| ClopidogrelClopidogrel Bisulfate | 299 | $4,443 |
| Ezetimibe | 142 | $4,148 |
| Atorvastatin Calcium | 262 | $3,728 |
| Valsartan | 60 | $2,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $238,549162 claims |
| NovartisEntresto | $297 | $142,743118 claims |
| Johnson & JohnsonXarelto | $195 | $63,95441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Rockville
- Mark TurcoRockville$25K
- Dennis DonohueRockville$19K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.